Members of the COW Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program. Listed below are the COW Board members.
Board Co-Chairs
Michael S. Saag, MD
Professor of Medicine
University of Alabama at Birmingham
Birmingham, Alabama
Dr Saag reported no relevant financial relationships with ineligible companies. (Updated September 10, 2025)
Marshall J. Glesby, MD, PhD
Professor of Medicine and Healthcare Policy and Research
Weill Cornell Medicine
New York, New York
Dr Glesby reported no relevant financial relationships with ineligible companies. (Updated September 24, 2025)
Board Members
Roger J. Bedimo, MD, MS
Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas
Dr Bedimo reported receiving research grants awarded to his institution from Merck & Co, Inc; and serving on the scientific advisory boards for Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc, Shionogi, and Janssen Pharmaceuticals. (Updated August 27, 2025)
Kara W. Chew, MD, MS
Assistant Professor of Medicine
University of California Los Angeles David Geffen School of Medicine
Los Angeles, California
Dr Chew reported medical writing support (no direct compensation) from Pfizer, Inc (Updated September 23, 2025)
Betty J. Dong, PharmD
Professor of Clinical Pharmacy
University of California San Francisco
San Francisco, California
Dr Dong reported no relevant financial relationships with ineligible companies. (Updated September 23, 2025)
Steven C. Johnson, MD
Professor of Medicine
University of Colorado School of Medicine
Aurora, Colorado
Dr Johnson has no relevant financial relationships with ineligible companies to disclose. (Updated July 28, 2025)
Carrie Down Johnston, MD
Assistant Professor of Medicine
Weill Cornell Medicine
New York, New York
Dr Johnston reported no relevant financial relationships with ineligible companies. (Updated September 25, 2025)
Harry W. Lampiris, MD
Professor of Clinical Medicine
University of California San Francisco
San Francisco, California
Dr Lampiris has no relevant financial relationships with ineligible companies to disclose. (Updated September 23, 2025)
David L. Wyles, MD
Chief of the Division of Infectious Diseases
Denver Health Medical Center
Denver, Colorado
Dr Wyles reported receiving consultant fees from Atea Pharmaceuticals. (August 25, 2025)
Planner
Donna M. Jacobsen
Executive Director/President
International Antiviral Society–USA
San Francisco, California
Ms Jacobsen reported no relevant financial relationships with ineligible companies. (Updated September 25, 2025)